Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 9/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470735 | 0.89 | NTRK1 (0.42) | RETNTRK1DPP4KDM4DRORC | |
| SCHEMBL457722 | 0.88 | NTRK1 (0.41) | RETNTRK1DPP4 | |
| SCHEMBL610961 | 0.88 | NTRK1 (0.41) | RETNTRK1DPP4RORC | |
| SCHEMBL458712 | 0.88 | NTRK1 (0.41) | RETNTRK1DPP4RORC | |
| SCHEMBL457724 | 0.88 | NTRK1 (0.41) | RETNTRK1DPP4 | |
| SCHEMBL470570 | 0.88 | NTRK1 (0.43) | RETNTRK1DPP4RORC | |
| SCHEMBL6128115 | 0.88 | NTRK1 (0.41) | RETNTRK1DPP4RORC | |
| SCHEMBL14722979 | 0.88 | NTRK1 (0.41) | RETNTRK1DPP4RORC | |
| SCHEMBL459231 | 0.88 | JAK3 (0.39) | AAK1RETNTRK1DPP4KDM4D | |
| SCHEMBL14723522 | 0.87 | NR1H2 (0.42) | RETNTRK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | AAK1 1673/4885CHRM2 740/4885RET 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.